RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Transcode Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.70+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.63M
- P/E (TTM)
- –
- Dividend yield
- –
Transcode Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Transcode Therapeutics | Industry median |
|---|---|---|
| Market Cap | $28.78M | $197.05M |
| Enterprise Value | $20.40M | $106.56M |
Income (trailing twelve months)
| Measure | Transcode Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$45.13M | -$21.44M |
| Net Income | -$42.83M | -$22.46M |
| EBITDA | -$45.10M | -$16.91M |
Returns
| Measure | Transcode Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -53.8% | -41.0% |
| Return on Capital Employed (ROCE) | -31.0% | -37.8% |
Balance sheet
| Measure | Transcode Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $8.38M | $62.42M |
| Net Cash (Debt) | $8.38M | $15.68M |
| Net Cash Per Share | $0.50 | $0.65 |
| Equity (Book Value) | -$27.69M | $48.79M |
| Book Value Per Share | -$1.64 | $1.36 |
| Tangible Book Value | -$167.74M | $23.06M |
| Working Capital | $5.24M | $75.77M |
Financial position
| Measure | Transcode Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.97 | 3.30 |
| Quick Ratio | 1.55 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Transcode Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$22.61M | -$12.35M |
Efficiency
| Measure | Transcode Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$3.57M | -$732.08K |
| Employee Count | 12 | 73 |
Dividends and yields
| Measure | Transcode Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -148.8% | -21.2% |
Shares
| Measure | Transcode Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 16,930,700 | 59,128,900 |
| Shares Change (YoY) | 247.2% | 11.1% |
| Shares Change (QoQ) | 10.3% | 0.54% |
| Shares Held by Institutions | 0.20% | 59.4% |
Scores
| Measure | Transcode Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.71 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Transcode Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.